Air purifier use and COPD health in adults: a home-based study
Official title: Respiratory Benefits of Indoor Air Purification in Patients With Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial
Run by Fudan University · NCT07505602 · Data updated 2026-11-12
This randomized trial tests whether using a real air purifier at home improves respiratory health in adults with COPD compared to a sham purifier.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Fudan University Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | March 30, 2026 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | June 9, 2026 |
| Trial ID | NCT07505602 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 50–80 with physician-diagnosed COPD who live in Shanghai and have no plans to move during the study.
✕Probably not a fit
Patients with comorbid conditions or environmental factors that negate indoor air quality improvements may see little to no benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, double-blind, parallel-controlled study assessing a 12-month home-based air purification intervention for adults with COPD in Shanghai. Participants are assigned to either an active HEPA/carbon-filter purifier or a sham device, with blinding of participants and outcome assessors. Participants undergo pulmonary function tests, impulse oscillometry, chest imaging, and patient-reported questionnaires at baseline and at 1, 3, 6, and 12 months, along with monthly telephone follow-ups and biological sample collection. Primary outcomes focus on respiratory health measures, while secondary assessments track quality of life and clinical status. The study aims to determine if improving indoor air quality can favorably impact COPD-related outcomes.
Why it matters
Potential benefit: If successful, patients with COPD could experience better breathing, fewer symptoms, and improved quality of life through cleaner indoor air.
How similar studies have gone: Prior studies in related respiratory conditions suggest indoor air quality improvements can influence respiratory outcomes, but this exact home-based COPD trial is novel in its design.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 50 and 80 years old * Physician diagnosis of COPD * Living in Shanghai during the intervention period * Subjects who have no plans to change homes during the intervention period * Non-smokers and former smokers Exclusion Criteria: * Subjects living in a location other than home * Subjects with a history of alcohol abuse * Subjects with other chronic lung diseases, such as active tuberculosis, pulmonary fibrosis, cystic fibrosis, or alpha-1 antitrypsin deficiency * Subjects with a history of thoracic surgery * Subjects with a history of malignant tumors, such as lung cancer, liver cancer, or gastric cancer * Subjects with diagnosed chronic hepatic or renal insufficiency, such as liver cirrhosis, chronic viral hepatitis, or autoimmune liver disease * Subjects with acute myocardial infarction or unstable arrhythmia diagnosed within the past 6 weeks * Subjects currently participating in other interventional studies
Where it's running
-
School of Public Health, Fudan University
Shanghai, China Recruiting
Study contacts
- Study coordinator: Haidong Kan, Ph.D
- Email: kanh@fudan.edu.cn
- Phone: +86-021-54237908
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease in Real World Practice
This study will look at real-world safety and effectiveness of disease-modifying therapy (DMT) in adults with MCI or Alzheimer's dementia by comparing those who receive DMT in routine care to those who do not.
-
ctDNA methylation-guided adjuvant therapy after removing colorectal liver metastases
This trial tests whether using a blood test that detects ctDNA methylation after surgery can guide adjuvant therapy for patients who had colorectal cancer spread to the liver and were operated on with no remaining disease.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer
This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.
-
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.
-
Hypofractionated vs. standard radiotherapy after mastectomy with implant reconstruction
This trial tests whether shorter, higher-dose radiotherapy schedules after implant-based mastectomy reconstruction work as well as the traditional longer schedules for preventing unplanned reoperations.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.